Business Context and Reporting Period
This Form 8-K, dated July 30, 2025, reports the completion of Supernus Pharmaceuticals, Inc.'s acquisition of Sage Therapeutics, Inc. The transaction involved a tender offer that expired on July 30, 2025, followed by a merger effective July 31, 2025, under which Sage became a wholly-owned subsidiary of Supernus.
Key Financial Metrics and Transaction Terms
- Aggregate Consideration: Approximately $561 million in cash (exclusive of Contingent Value Rights).
- Offer Price: $8.50 per share in cash plus one Contingent Value Right (CVR) per share.
- Tender Results: 36,313,509 shares validly tendered, representing approximately 58% of outstanding shares.
- Maximum CVR Liability: Approximately $234 million in aggregate contingent payments.
- Financial Statements: Not included in this filing; expected to be filed via amendment within 71 days.
Material Changes and Milestone Payments
The filing details the establishment of a Contingent Value Rights (CVR) Agreement with four potential milestone payments totaling up to $3.50 per CVR:
- $0.50 per CVR: Payable upon the first commercial sale in Japan of ZURZUVAE for Major Depressive Disorder by June 30, 2026.
- $1.00 per CVR: Payable if U.S. Net Sales of ZURZUVAE reach $250 million in a calendar year by December 31, 2027.
- $1.00 per CVR: Payable if U.S. Net Sales of ZURZUVAE reach $300 million in a calendar year by December 31, 2028.
- $1.00 per CVR: Payable if U.S. Net Sales of ZURZUVAE reach $375 million in a calendar year by December 31, 2030.
Equity awards (options, RSUs, PSUs) were converted to cash payments based on the $8.50 closing amount and CVRs, with out-of-the-money options cancelled without payment.
Outlook, Risks, and Management Commentary
Management notes that there can be no assurance that any CVR milestones will be achieved or payments made. The filing includes standard forward-looking statements regarding risks such as the ability to sustain profitability, raise capital, commercialize products, and obtain regulatory approvals. Specific risks include the timing of clinical trials, intellectual property protection, and market size estimates.
Investor Verification Checklist
- Verify the final number of shares tendered and the total cash payout once the transaction settles.
- Monitor the regulatory status of ZURZUVAE in Japan for the first CVR milestone.
- Track U.S. Net Sales of ZURZUVAE against the $250M, $300M, and $375M thresholds for subsequent CVR payments.
- Review the upcoming amendment to this 8-K for required financial statements and transaction expense details.
- Assess the impact of the $561 million cash outflow on Supernus's liquidity and debt capacity.